Immunotherapy

Bolt's lead candidate, BDC-1001, is an immune-stimulating antibody conjugate currently being studied in a Phase I clinical trial in HER2-expressing solid tumors.

A study found that patients with a mutation in ARID1A and expression of immune cytokine CXCL13 had better overall survival on immune checkpoint inhibitors.

The company will initiate a Phase I/II clinical trial in patients with HER2-positive solid tumors later this year.

The Phase IB trial will test whether UbiVac's cancer vaccine combined with BMS' T cell agonist and Opdivo can stimulate anti-cancer immunity in advanced TNBC patients.

The company will start Phase I/II trials to evaluate the safety and anti-tumor activity of its natural killer cells in combination with Herceptin or Erbitux in the third quarter of 2020.

Researchers also found that a subgroup of patients who had been hormone receptor-positive and converted to TNBC status responded especially well to the therapy.

WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.

Researchers reported that when CDK12-mutated patients were treated with PD-1 inhibitors in fourth- or later-line settings, a third of them responded.

PRGN-2009 showed anti-tumor activity in preclinical studies and now will be evaluated in humans as a monotherapy and in combination with a bifunctional fusion protein.